Alterity Therapeutics Parkinson's Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting

Core Insights - Alterity Therapeutics presented significant findings at the American Academy of Neurology (AAN) 2024 Annual Meeting regarding ATH434, a potential treatment for Parkinson's disease and Multiple System Atrophy (MSA) [1][2] Group 1: ATH434 Clinical Trials - ATH434-201 Phase 2 clinical trial involves 65 participants diagnosed with early-stage MSA, focusing on fluid biomarkers and neuroimaging data [3] - The trial aims to demonstrate the efficacy of ATH434 in redistributing excess labile iron, inhibiting α-synuclein aggregation, and reducing oxidative stress [3][8] - The study enrolled 77 adults, with treatment lasting 12 months to assess changes in efficacy endpoints [8] Group 2: Biomarker Insights - Baseline data from the ATH434-201 trial indicated elevated plasma Neurofilament Light Chain (NfL) levels correlated with disease severity in MSA patients [2][3] - The bioMUSE Natural History Study highlighted the aggressive progression of MSA and the potential of NfL as a biomarker for tracking disease progression [5][10] Group 3: Preclinical Findings - In a primate model, ATH434 treatment resulted in improved motor performance and reduced iron levels in the substantia nigra, supporting its potential for treating Parkinson's disease [6] - The study showed that all six ATH434-treated macaques had stable or improving scores, while two of three vehicle-treated macaques did not demonstrate improvement [6] Group 4: Company Overview - Alterity Therapeutics is focused on developing disease-modifying treatments for neurodegenerative diseases, with ATH434 being its lead candidate [7][13] - The company has received Orphan drug designation for ATH434 for the treatment of MSA from the U.S. FDA and the European Commission [7]